By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



The John Hancock Tower, 54th Floor
200 Clarendon Street
Boston  Massachusetts  02116  U.S.A.
Phone: 617-425-9200 Fax: 617-425-9201



Company News
FDA Office Of Orphan Products Development Awards Rhythm $1 Million Grant To Support Phase 2 Study Of Setmelanotide In Prader-Willi Syndrome 9/24/2015 10:17:41 AM
Rhythm Initiates Two Phase 2 Clinical Trials Of Setmelanotide (RM-493) In Rare Genetic Disorders Of Obesity Caused By MC4 Pathway Deficiencies 6/4/2015 6:25:50 AM
Rhythm Initiates Phase 2b Clinical Trial Of Relamorelin For Diabetic Gastroparesis 4/8/2015 6:14:13 AM
Rhythm Appoints Fred T. Fiedorek, M.D., Chief Medical Officer 12/11/2014 7:48:14 AM
Boston’s Rhythm Withdraws $86 Million IPO Citing Acquisition Agreement With Actavis (ACT) 10/30/2014 6:30:15 AM
Rhythm Presents Positive Phase 2 Study Results For Relamorelin For Chronic Constipation 10/24/2014 7:54:23 AM
Boston's Rhythm Files For $86 Million IPO 8/27/2014 2:52:16 PM
Rhythm Presents Clinical Data That RM-493 Increases Energy Expenditure In Obesity Study 6/23/2014 6:50:50 AM
Rhythm Presents Positive GI Motility Results For Relamorelin (RM-131) In Phase 2 Chronic Constipation Study 5/6/2014 9:49:25 AM
Rhythm Presents Positive Phase 2 Study Results For Ghrelin Prokinetic Relamorelin (RM-131) In Diabetic Gastroparesis 5/6/2014 9:48:22 AM